Valion Bio, Inc. (VBIO) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Valion Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.554 -- 00:00:07.101 Welcome to Valiant Bio, Inc.' 's conference call to discuss first quarter 2026 00:00:07.101 -- 00:00:09.464 financial results. 00:00:09.464 -- 00:00:14.469 This call has been pre-recorded. The call is being webcast and the replay will be 00:00:14.469 -- 00:00:20.216 available on the investors section of the company's website for 90 days. 00:00:20.216 -- 00:00:25.562 Before we begin, please note that during today's call, management will make various forward-looking 00:00:25.562 -- 00:00:27.048 statements. 00:00:27.048 -- 00:00:32.055 Investors are cautioned that these forward-looking statements are based on current expectations 00:00:32.055 -- 00:00:37.423 and are subject to risks and uncertainties that could cause actual results or outcomes 00:00:37.423 -- 00:00:42.510 to differ materially from those indicated in the forward-looking statements. 00:00:42.510 -- 00:00:47.737 Forward-looking statements include, without limitation, statements regarding the FDA's 00:00:47.737 -- 00:00:53.866 animal rule pathway and the development of entolamide and entolasta, 00:00:53.866 -- 00:00:59.118 the company's engagement with BARDA, NIAID, the Department of War, and 00:00:59.118 -- 00:01:04.284 other U.S. and allied government agencies, the activation, scale-up, and 00:01:04.284 -- 00:01:08.349 customer development plans of Velocity Bioworks, 00:01:08.349 -- 00:01:13.335 the company's continued listing on NASDAQ, the company's working capital and ability 00:01:13.335 -- 00:01:20.020 to access additional financing, and the consummation of any strategic transactions. 00:01:20.083 -- 00:01:24.288 Please read the safe harbor statement contained in the press release that Valiant Bio, 00:01:24.288 -- 00:01:29.299 Inc. issued today, as well as the risk...